By Anthony O. Goriainoff
MaxCyte said it would propose a delisting of its shares on London's AIM to shareholders but will retain its listing on the Nasdaq Global Select Market.
The cell-engineering company said the board believed that delisting has the potential to enhance the liquidity of trading in the common stock on Nasdaq and reduce the duplication of costs arising from retaining two listings. It added that the vast majority of trading on its common stock--around 94% over the past year--takes place on the Nasdaq exchange, and that the future benefits of staying on AIM are limited.
The company said it has kept a listing on AIM for over nine years but that following its listing on Nasdaq around four years ago its trading in London fell to a level which the board believes no longer justifies maintaining a dual listing.
Still, the company said it would continue to engage with U.K.-based shareholders.
The company said it will consult the delisting proposal with shareholders at its annual meeting, scheduled for June 18, and that if approved it expects its last day of trading on AIM to be June 25.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
April 15, 2025 03:01 ET (07:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。